SEP-4199

SEP-4199 is a non-racemic amisulpride engineered to have higher binding affinity for the 5-HT7 receptor and lower affinity for the D2 receptor compared to conventional racemic amisulpride. It contains the R- and S-enantiomers of amisulpride in an 85:15 ratio rather than a 50:50 ratio. The modification is hoped to give the compound improved efficacy and fewer side effects. It is under development for the treatment of depression in people with bipolar disorder. If approved, it would be the first amisulpride approved in the US for psychiatric indications. It is in a phase III trial as of 2023.